TRx0237 induces apoptosis and enhances anti-PD-1 immunotherapeutic efficacy in anaplastic thyroid Cancer

Area of Science:

• Oncology
• Cancer Therapeutics
• Molecular Biology

Background:

• Anaplastic thyroid cancer (ATC) is an aggressive malignancy with limited therapeutic options and poor patient outcomes.
• There is a critical need for novel treatment strategies to combat the lethality of ATC.

Purpose of the Study:

• To identify potential therapeutic agents for anaplastic thyroid cancer.
• To investigate the mechanism of action of TRx0237, a tau protein inhibitor, in ATC.
• To evaluate the synergistic potential of TRx0237 with anti-PD-1 immunotherapy.

Main Methods:

• Drug library screening to identify compounds with inhibitory effects on ATC cells.
• In vitro studies to elucidate the mechanism of TRx0237, including apoptosis induction and reactive oxygen species (ROS)-mediated endoplasmic reticulum stress.
• In vivo validation using ATC xenograft models and patient-derived organoids, assessing TRx0237 efficacy and PD-L1 expression.

Main Results:

• TRx0237 demonstrated significant inhibitory effects on ATC cell proliferation.
• The anti-cancer activity of TRx0237 was attributed to the induction of apoptosis via ROS-mediated endoplasmic reticulum stress.
• TRx0237 upregulated PD-L1 expression in ATC and synergistically enhanced the efficacy of anti-PD-1 therapy in preclinical models.

Conclusions:

• TRx0237 exhibits potent anticancer effects in anaplastic thyroid cancer by inducing apoptosis.
• TRx0237 enhances the efficacy of anti-PD-1 immunotherapy, suggesting a combination therapy approach.
• TRx0237 represents a promising therapeutic candidate for the treatment of anaplastic thyroid cancer.